目的评价祛邪胶囊对晚期结直肠癌患者中位生存期和生活质量的影响。方法采用随机对照临床研究方法,纳入晚期结直肠癌患者40例,可评价37例,治疗组18例,对照组19例,两组均采用化疗(FOLFOX、FOLFRI方案)等西医治疗,治疗组在此基础上加用祛...目的评价祛邪胶囊对晚期结直肠癌患者中位生存期和生活质量的影响。方法采用随机对照临床研究方法,纳入晚期结直肠癌患者40例,可评价37例,治疗组18例,对照组19例,两组均采用化疗(FOLFOX、FOLFRI方案)等西医治疗,治疗组在此基础上加用祛邪胶囊,治疗3个月后,进行长期随访,观察患者的病死率、生存期、中位生存期、疾病进展期(time to progression,TTP)及生活质量。结果治疗组和对照组的病死率分别为11.1%(2/18)和42.1%(8/19);生存期分别为(22.63±7.34)个月和(19.76±8.28)个月,中位生存期分别为17个月和13个月;TTP分别为(17.76±5.62)个月和(12.68±9.26)个月,经统计分析均有统计学意义(P<0.05)。中医症状积分、生活质量及KPS评分治疗组治疗前分别为15.59±3.78、54.06±3.96、64.71±6.24,治疗后分别为10.53±5.57、58.65±4.03、69.41±4.29,治疗前后比较差异均有统计学意义(P<0.05);对照组治疗前分别为16.11±3.99、54.06±4.39及64.44±5.11;治疗后分别为19.61±7.78、50.17±8.26、60.00±9.70,治疗前后生活质量及KPS评分比较差异有统计学意义(P<0.05),但趋势是向差的方向。结论晚期结直肠癌患者加用祛邪胶囊,能减少病死率,延长生存期、中位生存期和TTP,提高生活质量。展开更多
Objective： To evaluate the effectiveness of a comprehensive therapy of traditional Chinese medicine （TCM） in reducing the relapse and metastasis of stage Ⅱ and Ⅲ colorectal cancer based on conventional Western me...Objective： To evaluate the effectiveness of a comprehensive therapy of traditional Chinese medicine （TCM） in reducing the relapse and metastasis of stage Ⅱ and Ⅲ colorectal cancer based on conventional Western medicine （WM） therapy. Methods： Two hundred and twenty-two patients in total, diagnosed as stage Ⅱ and Ⅲ colorectal cancer from February 2000 to March 2006, were recruited from Xiyuan Hospital, China Academy of Chinese Medical Sciences and the General Hospital of Beijing Military Area. They were followed-up once every 3-6 months. Twenty cases dropped out from the cohort. The remaining 202 patients were all treated with routine WM treatment [including R0 radical operation, or chemotherapy or/and radiotherapy according to national comprehensive cancer network （NCCN） clinical guidelines]. These patients were assigned to two groups based on whether or not they were additionally treated with TCM comprehensive therapy （orally administered with a decoction according to syndrome differentiation, combined with a traditional patent drug over one year）. Ninety-eight patients from Xiyuan Hospital were treated with WM and TCM （combined group）, and 104 patients from the General Hospital of Beijing Military Area were treated with WM alone （WM group）. The demographic data at baseline were comparable, including the operation times, age, sex, TNM staging, and pathological types. The patients were followed-up for one to five years. Up to now, there are 98, 98, 77, 64, and 47 patients with 1, 2, 3, 4, and 5 years of follow-up in the combined group, respectively; and 104, 104, 97, 81, and 55 patients in the WM group, respectively. The results of the 5-year follow-up of all the patients will be available in 2011. Results： The relapse/metastasis rate of 1-, 2-, 3-, 4-, and 5-year were 0 （0/98）, 2.04% （2/98）, 11.69% （9/77）, 14.06% （9/64）, and 21.28% （10/47） in the combined group, and were 4.80%（5/104）, 16.35% （17/104）, 21.65% （21/97）, 25.93% （21/81）, and 38.展开更多
文摘目的评价祛邪胶囊对晚期结直肠癌患者中位生存期和生活质量的影响。方法采用随机对照临床研究方法,纳入晚期结直肠癌患者40例,可评价37例,治疗组18例,对照组19例,两组均采用化疗(FOLFOX、FOLFRI方案)等西医治疗,治疗组在此基础上加用祛邪胶囊,治疗3个月后,进行长期随访,观察患者的病死率、生存期、中位生存期、疾病进展期(time to progression,TTP)及生活质量。结果治疗组和对照组的病死率分别为11.1%(2/18)和42.1%(8/19);生存期分别为(22.63±7.34)个月和(19.76±8.28)个月,中位生存期分别为17个月和13个月;TTP分别为(17.76±5.62)个月和(12.68±9.26)个月,经统计分析均有统计学意义(P<0.05)。中医症状积分、生活质量及KPS评分治疗组治疗前分别为15.59±3.78、54.06±3.96、64.71±6.24,治疗后分别为10.53±5.57、58.65±4.03、69.41±4.29,治疗前后比较差异均有统计学意义(P<0.05);对照组治疗前分别为16.11±3.99、54.06±4.39及64.44±5.11;治疗后分别为19.61±7.78、50.17±8.26、60.00±9.70,治疗前后生活质量及KPS评分比较差异有统计学意义(P<0.05),但趋势是向差的方向。结论晚期结直肠癌患者加用祛邪胶囊,能减少病死率,延长生存期、中位生存期和TTP,提高生活质量。
基金Supported by Norway National Evidence Based Medicine to Provide Financial Assistance Project(No.0221)
文摘Objective： To evaluate the effectiveness of a comprehensive therapy of traditional Chinese medicine （TCM） in reducing the relapse and metastasis of stage Ⅱ and Ⅲ colorectal cancer based on conventional Western medicine （WM） therapy. Methods： Two hundred and twenty-two patients in total, diagnosed as stage Ⅱ and Ⅲ colorectal cancer from February 2000 to March 2006, were recruited from Xiyuan Hospital, China Academy of Chinese Medical Sciences and the General Hospital of Beijing Military Area. They were followed-up once every 3-6 months. Twenty cases dropped out from the cohort. The remaining 202 patients were all treated with routine WM treatment [including R0 radical operation, or chemotherapy or/and radiotherapy according to national comprehensive cancer network （NCCN） clinical guidelines]. These patients were assigned to two groups based on whether or not they were additionally treated with TCM comprehensive therapy （orally administered with a decoction according to syndrome differentiation, combined with a traditional patent drug over one year）. Ninety-eight patients from Xiyuan Hospital were treated with WM and TCM （combined group）, and 104 patients from the General Hospital of Beijing Military Area were treated with WM alone （WM group）. The demographic data at baseline were comparable, including the operation times, age, sex, TNM staging, and pathological types. The patients were followed-up for one to five years. Up to now, there are 98, 98, 77, 64, and 47 patients with 1, 2, 3, 4, and 5 years of follow-up in the combined group, respectively; and 104, 104, 97, 81, and 55 patients in the WM group, respectively. The results of the 5-year follow-up of all the patients will be available in 2011. Results： The relapse/metastasis rate of 1-, 2-, 3-, 4-, and 5-year were 0 （0/98）, 2.04% （2/98）, 11.69% （9/77）, 14.06% （9/64）, and 21.28% （10/47） in the combined group, and were 4.80%（5/104）, 16.35% （17/104）, 21.65% （21/97）, 25.93% （21/81）, and 38.
